Financials Prediction Markets

FDA decision: Venglustat by Sanofi (in 2026)
$1,926 vol
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
$7,339 vol
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
$1,669 vol
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
$8,296 vol
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
$17,776 vol
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
$2,361 vol